In the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial, two NT-pro BNP measurements (6 months apart) in patients (n = 5380) with T2DM effectively identified those at the highest risk of developing symptomatic HF. This evidence concerns the gene NPPB and hydrops fetalis.